• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Oral Mucositis - Pipeline Review, H2 2012 Product Image

Oral Mucositis - Pipeline Review, H2 2012

  • ID: 2233797
  • August 2012
  • 76 pages
  • Global Markets Direct

Oral Mucositis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Oral Mucositis - Pipeline Review, H2 2012', provides an overview of the Oral Mucositis therapeutic pipeline. This report provides information on the therapeutic development for Oral Mucositis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oral Mucositis. 'Oral Mucositis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oral Mucositis.
- A review of the Oral Mucositis products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Oral Mucositis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Oral Mucositis 9
Oral Mucositis Therapeutics under Development by Companies 11
Oral Mucositis Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Oral Mucositis Therapeutics – Products under Development by Companies 19
Oral Mucositis Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Oral Mucositis Therapeutics Development 21
Biotec Pharmacon ASA 21
Daewoong Pharmaceutical Co., Ltd. 22
BioAlliance Pharma SA 23
Sucampo Pharmaceuticals, Inc. 24
PolyMedix, Inc. 25
ActogeniX NV 26
Alder Biopharmaceuticals Inc. 27
Avaxia Biologics, Inc. 28
Canopus BioPharma Incorporated 29
Nephrx Corporation 30
Oral Mucositis – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AG013 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Clonidine Lauriad - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Easyef - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cobiprostone - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ALD-518 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PMX-30063 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CB1400 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Celecoxib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Pilocarpine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Traumeel S - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Soluble Beta Glucan - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Kepivance - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Doxycycline Hyclate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NX002 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Hybrid Adenoretroviral Vectors - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Dexpanthenol - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
HO/03/09 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Regenasyn - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
GC-4403 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Oral Mucositis Therapeutics – Drug Profile Updates 58
Oral Mucositis Therapeutics – Discontinued Products 66
Oral Mucositis Therapeutics - Dormant Products 67
Oral Mucositis – Product Development Milestones 68
Featured News & Press Releases 68
Jul 20, 2012: Piramal Healthcare Receives Approval For Conducting Phase II Clinical Trial Of P276 68
Jun 28, 2012: Access Pharma Announces Positive Data From MuGard Phase IV Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium 69
Jun 26, 2012: Access Pharma To Report New MuGard Clinical Trial Data At MASCC/ISOO Symposium 70
Apr 17, 2012: BioAlliance Pharma Announces New Achievements In Phase II Clinical Trial Of Clonidine Lauriad 71
Apr 17, 2012: Access Pharma Announces Interim Data From MuGard Phase IV Clinical Trial In Oral Mucositis 71
Apr 04, 2012: Access Pharmaceuticals Announces Addition Of MuGard On Formulary At Memorial Sloan-Kettering Cancer Center 72
Mar 02, 2012: SciClone Announces Results Of Interim Analysis Of Phase II SCV-07 Oral Mucositis Trial 72
Feb 24, 2012: Rhei Pharmaceuticals Receives Final Marketing Approval From SFDA Of China For MuGard 73
Nov 30, 2011: NephRx Receives US Patent For NX002 For Treatment Of Oral Mucositis 74
Nov 02, 2011: BioAlliance Pharma Receives Orphan Designation For Clonidine Lauriad In Europe 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables
Number of Products Under Development for Oral Mucositis, H2 2012 9
Products under Development for Oral Mucositis – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 20
Biotec Pharmacon ASA, H2 2012 21
Daewoong Pharmaceutical Co., Ltd., H2 2012 22
BioAlliance Pharma SA, H2 2012 23
Sucampo Pharmaceuticals, Inc., H2 2012 24
PolyMedix, Inc., H2 2012 25
ActogeniX NV, H2 2012 26
Alder Biopharmaceuticals Inc., H2 2012 27
Avaxia Biologics, Inc., H2 2012 28
Canopus BioPharma Incorporated, H2 2012 29
Nephrx Corporation, H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Oral Mucositis Therapeutics – Drug Profile Updates 58
Oral Mucositis Therapeutics – Discontinued Products 66
Oral Mucositis Therapeutics – Dormant Products 67

List of Figures
Number of Products under Development for Oral Mucositis, H2 2012 9
Products under Development for Oral Mucositis – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos